KEQU

主要经营地：US

详细生意模式：Manufacturer of laboratory furniture, fume hoods, and containment systems for research and industrial facilities. Recent acquisition of Nu Aire Inc. added biosafety and containment technologies, strengthening product portfolio and geographic presence. Serves academic institutions, pharmaceutical companies, biotech firms, and government laboratories. Backlog at $183M demonstrates strong demand visibility. International segment (particularly India) growing at 21.4% fueling expansion beyond domestic market.

护城河：🟡 Medium

估值水平：PE not disclosed, EV/EBITDA 4.71x

EV/Market Cap：EV $150.5M / MC $97.5M

网络观点：Q3 revenue $69.4M with 3.3% growth; international segment led growth at +21.4% from India operations. Backlog of $183M provides strong visibility. Net debt halved, improving financial flexibility. Nu Aire acquisition infrastructure positions company for M&A consolidation in fragmented lab equipment market. Growth trajectory supported by backlog and international expansion.

AI观点：Web search confirms strong Q3 fiscal 2026 results with $69.4M revenue (+3.3% YoY) and 25.8% pre-tax earnings growth. Royce & Associates purchased 38,990 shares for $1.66M, signaling institutional confidence. EV/EBITDA 4.71x is reasonable for growth segment. Backlog of $183M provides high revenue visibility extending several quarters. Nu Aire acquisition appears well-integrated, contributing meaningfully to results. India's 21.4% growth is strongest geographic segment, indicating exposure to secular biotech/pharma growth drivers. Concern: Q3 growth of 3.3% suggests organic growth may be moderating, with acquisition doing heavy lifting. Trading above recent acquisition price suggests market confidence in management's ability to integrate acquisitions and drive consolidation strategy.